AXSM Investors Have Opportunity to Lead Axsome Therapeutics, Inc. Securities Fraud Lawsuit

<br /> AXSM Investors Have Opportunity to Lead Axsome Therapeutics, Inc. Securities Fraud Lawsuit<br />

PR Newswire

Shareholders with

$500,000

losses or more are encouraged to contact the firm.

LOS ANGELES

,

June 3, 2022

/PRNewswire/ —

The Law Offices of

Frank R. Cruz

announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against

Axsome

Therapeutics, Inc. (”

Axsome

” or the “Company”) (

NASDAQ

:

AXSM

).

Class Period:

December 30, 2019

–

April 22, 2022

Lead Plaintiff Deadline:

July 12, 2022

If you are a shareholder who suffered a loss, click

here

to participate.

The complaint filed alleges that, throughout the Class Period, Defendants failed to disclose to investors that: (1) Axsome’s CMC practices were deficient with respect to AXS-07 and its manufacturing process; (2) as a result, Axsome was unlikely to submit the AXS-07 NDA on its initially represented timeline; (3) the foregoing CMC issues remained unresolved at the time that the FDA reviewed the AXS-07 NDA; (4) accordingly, the FDA was unlikely to approve the AXS-07 NDA; (5) as a result of all the foregoing, Axsome had overstated AXS-07’s regulatory and commercial prospects; and (6) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact

Frank R. Cruz

, of The Law Offices of

Frank R. Cruz

, 1999 Avenue of the Stars, Suite 1100,

Los Angeles, California

90067 at 310-914-5007, by email to

[email protected]

, or visit our website at

www.frankcruzlaw.com

. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.